How This Works
Neuroxelin is designed to intervene in the cascade of brain injury through multiple mechanisms. It may dampen excitotoxic neuron death by disrupting NMDA receptor signaling pathways, similar to nerinetide (NA-1), which interferes with PSD-95 protein interactions[1]. Additionally, Neuroxelin-class peptides can reduce neuroinflammation by downregulating microglial activation and cytokine release, as demonstrated in studies of apoE-mimetic peptides like CN-105[2]. The peptide may also provide neurotrophic support by promoting synaptic repair and neurogenesis, supporting neuronal survival and vascular repair following acute brain injuries[3][7].
References
The Lancet
— Efficacy and safety of nerinetide for acute ischaemic stroke (ESCAPE-NA1): Phase 3 RCT of PSD-95 inhibitor peptide
Scientific Reports (Nature)
— Neuroprotective pentapeptide CN-105 reduces sterile inflammation and improves outcomes in TBI murine model
Drugs (Springer/PubMed)
— Efficacy and safety of sovateltide in acute cerebral ischaemic stroke: Phase III clinical trial
Nutrients (PMC)
— Neuropsychological performance after extended N-Pep-12 supplementation in ischemic stroke (12-month study)
GenScript
— Peptide storage and handling guidelines: stability, reconstitution, and freeze-thaw considerations
NIBSC (UK MHRA)
— Peptide handling, dissolution, and storage guidelines from standards agency
Biochimica et Biophysica Acta (ScienceDirect)
— Advances in clinical studies of peptide drugs in stroke disease: mechanisms and progress
Stroke (AHA Journals)
— Factors influencing nerinetide effect on infarct volume in stroke research samples
PubMed
— Phase 1 randomized, double-blind, placebo-controlled study of CN-105 safety and pharmacokinetics
CDC
— Vaccine preparation: handling reference (angle, site, no aspiration)
CDC
— Vaccine preparation during vaccination: measurement guidance
Advances in Research (PMC)
— measurement of drugs: factors influencing pain sensation at preparation area
Translational Psychiatry (Nature)
— Davunetide effects on memory in prodromal Alzheimer’s disease
Schizophrenia Research (ScienceDirect)
— Effect of the neuroprotective peptide davunetide (AL-108) on cognition and safety